Establishing an immune correlate of protection for Nipah virus in nonhuman primates.

IF 6.9 1区医学 Q1 IMMUNOLOGY NPJ Vaccines Pub Date : 2024-12-19 DOI:10.1038/s41541-024-01036-2

V H Leyva-Grado, D Promeneur, K N Agans, G G Lazaro, V Borisevich, D J Deer, A Luckay, M Egan, A S Dimitrov, B Small, C C Broder, R W Cross, S Hamm, T W Geisbert

{"title":"Establishing an immune correlate of protection for Nipah virus in nonhuman primates.","authors":"V H Leyva-Grado, D Promeneur, K N Agans, G G Lazaro, V Borisevich, D J Deer, A Luckay, M Egan, A S Dimitrov, B Small, C C Broder, R W Cross, S Hamm, T W Geisbert","doi":"10.1038/s41541-024-01036-2","DOIUrl":null,"url":null,"abstract":"<p><p>The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"244"},"PeriodicalIF":6.9000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659318/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-01036-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

建立非人灵长类对尼帕病毒的免疫保护相关性。

人类人畜共患尼帕病毒感染的有限但反复暴发、其高致死率以及病毒在人与人之间的潜在传播使尼帕病毒成为具有大流行潜力的令人担忧的威胁。目前还没有获得许可的疫苗来预防感染和疾病。一种重组亨德拉病毒可溶性G糖蛋白疫苗（HeV-sG-V）候选疫苗最近在一项I期临床试验中进行了测试。由于NiV暴发是零星的，并且只有少数病例，许可可能需要另一种监管许可途径。因此，确定一个可靠的疫苗相关保护（CoP）将是至关重要的。我们评估了HeV-sG-V在非洲绿猴中引发的免疫反应及其与抗NiV攻击的关系。数据显示特异性结合和中和抗体滴度值预测了生存，并使我们能够为NiV孟加拉国和马来西亚菌株建立机制CoP。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.